<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513487650</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513487650</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impairment of vascular endothelial function following reperfusion therapy in patients with acute myocardial infarction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Zhaoying</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487650">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487650">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jinliang</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487650">1</xref>
<xref ref-type="aff" rid="aff2-0300060513487650">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kong</surname><given-names>Jian</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487650">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wu</surname><given-names>Suisheng</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513487650">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513487650"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513487650"><label>1</label>Cadre Ward, First Hospital, Jilin University, Changchun, China</aff>
<aff id="aff2-0300060513487650"><label>2</label>Cadre Ward, Heilongjiang Provincial Hospital, Harbin, China</aff>
<author-notes>
<corresp id="corresp1-0300060513487650">Dr Suisheng Wu, Cadre Ward, First Hospital, Jilin University, 71 Xinmin Street, Changchun 130021, China. Email: <email>suishengwu@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>1074</fpage>
<lpage>1078</lpage>
<history>
<date date-type="received"><day>13</day><month>12</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>3</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec12-0300060513487650"><title>Objective</title>
<p>To investigate vascular endothelial impairment as a result of reperfusion therapy in patients with acute myocardial infarction (AMI).</p>
</sec>
<sec id="sec13-0300060513487650"><title>Methods</title>
<p>Patients with AMI underwent reperfusion therapy (percutaneous cardiac intervention [PCI] or thrombolytic therapy) or conservative drug therapy. Healthy control subjects were recruited. Endothelial impairment was assessed via endothelial nitric oxide (NO) synthase (eNOS), NO and endothelin-1 (ET-1) levels, 24 h after reperfusion or on enrolment, as appropriate.</p>
</sec>
<sec id="sec14-0300060513487650"><title>Results</title>
<p>Patients who underwent PCI (<italic>n</italic> = 47) or thrombolytic therapy (<italic>n</italic> = 45) had significantly lower eNOS and NO levels, and higher ET-1 levels than those who received conservative drug therapy (<italic>n</italic> = 46). All patient groups had significantly lower eNOS and NO levels, and higher ET-1 levels, than controls (<italic>n</italic> = 45). There was a significant positive correlation between eNOS and NO, as well as significant negative correlations between eNOS/ET-1 and NO/ET-1 in all four groups.</p>
</sec>
<sec id="sec15-0300060513487650"><title>Conclusions</title>
<p>Patients with AMI who underwent reperfusion therapy displayed low eNOS activity. This may result in impairment of endothelial function via downregulation of NO and upregulation of ET-1.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Acute myocardial infarction</kwd>
<kwd>reperfusion therapy</kwd>
<kwd>endothelial nitric oxide synthase (eNOS)</kwd>
<kwd>nitric oxide</kwd>
<kwd>endothelin-1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513487650" sec-type="intro"><title>Introduction</title>
<p>The development of coronary heart disease is associated with many pathological factors.<sup><xref ref-type="bibr" rid="bibr1-0300060513487650">1</xref></sup> Acute myocardial infarction (AMI) is the main cause of sudden death throughout the world,<sup><xref ref-type="bibr" rid="bibr2-0300060513487650">2</xref></sup> and the timely and effective control of AMI occurrence and development is a primary focus of medical research. Reperfusion therapy is an effective and life-saving treatment for AMI<sup><xref ref-type="bibr" rid="bibr3-0300060513487650">3</xref></sup> that results in improved cardiac vascular endothelial function.<sup><xref ref-type="bibr" rid="bibr4-0300060513487650">4</xref></sup> Other studies have revealed impairment of general vascular endothelial function following reperfusion therapy, however.<sup><xref ref-type="bibr" rid="bibr5-0300060513487650">5</xref></sup></p>
<p>Nitric oxide (NO) is an indicator of vascular endothelial function,<sup><xref ref-type="bibr" rid="bibr6-0300060513487650">6</xref></sup> and a combination of NO and endothelin-1 (ET-1) is commonly used for clinical determination and analysis of vascular endothelial function.<sup><xref ref-type="bibr" rid="bibr7-0300060513487650">7</xref></sup> NO and ET-1 interact such that when the NO level increases, the attendant ET-1 level correspondingly decreases and vice versa.<sup><xref ref-type="bibr" rid="bibr8-0300060513487650">8</xref></sup> Abnormalities in this system can lead to disequilibrium in vascular endothelial function, resulting in pathological changes.<sup><xref ref-type="bibr" rid="bibr9-0300060513487650">9</xref></sup> NO is synthesized by endothelial NO synthase (eNOS), which has been shown to play an important role in cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr10-0300060513487650">10</xref></sup></p>
<p>The aims of the present study were to investigate vascular endothelial impairment via eNOS, NO and ET-1, in patients with AMI who had undergone reperfusion therapy.</p>
</sec>
<sec id="sec2-0300060513487650" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513487650"><title>Study population</title>
<p>The study recruited patients with AMI (diagnosed according to World Health Organization criteria<sup><xref ref-type="bibr" rid="bibr11-0300060513487650">11</xref></sup>) who were treated in the Cardiology Department, Heilongjiang Provincial Hospital, Harbin, China, between June 2010 and June 2011. Exclusion criteria were: (i) vascular atherosclerotic plaque, thrombosis or irregular stenosis in bilateral carotid artery or bilateral lower extremity arteries on colour Doppler ultrasonography examination; (ii) clinical manifestation of ischaemic disease of the lower extremity, including intermittent claudication and ischaemic pain; (iii) history of cerebral infarction or visible cerebral ischaemic lesions on computed tomography or magnetic resonance imaging; (iv) family history of hypertension; (v) diabetes; (vi) any malignant disease, severe liver disease, nephritis, infectious disease, recent trauma or surgery (within 1 year), or severe mental illness. Patients were divided between three groups according to a computer-generated randomization schedule: reperfusion by percutaneous coronary intervention (PCI); reperfusion by thrombolytic therapy; conservative drug therapy.</p>
<p>The control group comprised healthy individuals free from the exclusion criteria (described above), attending the Health Examination Centre, Heilongjiang Provincial Hospital, Harbin, China for routine health screening.</p>
<p>Peripheral blood samples were obtained after a 12-h fast within 24 h after reperfusion therapy or at enrolment, as appropriate. Immediately after collection, samples for eNOS and NO quantification (3 ml each) were centrifuged at 3000 <bold><italic>g</italic></bold> for 15 min at 20℃, and the resulting serum was collected and stored at −20℃ until use. Blood samples for ET-1 analysis were collected at the same time: for these analyses, 3-ml samples of peripheral blood were collected in sterile tubes containing 15 IU/ml heparin.</p>
<p>The study was conducted in accordance with the Declaration of Helsinki,<sup><xref ref-type="bibr" rid="bibr12-0300060513487650">12</xref></sup> and was approved by the Ethics Committee of First Hospital, Jilin University, Changchun, China (D5395L00006). All participants provided written informed consent prior to enrolment.</p>
</sec>
<sec id="sec4-0300060513487650"><title>eNOS activity</title>
<p>A colorimetric assay kit was used to quantify eNOS activity (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer’s instructions.</p>
</sec>
<sec id="sec5-0300060513487650"><title>NO quantification</title>
<p>Serum NO levels were quantified using an NO nitrate reductase assay kit (Nanjing Jiancheng Biochemical Co., Ltd., Nanjing, China), according to the manufacturer’s instructions, and expressed as µmol/l NO<sup>3−</sup>.</p>
</sec>
<sec id="sec6-0300060513487650"><title>ET-1 quantification</title>
<p>Quantification of plasma ET-1 was performed using a radioimmunoassay kit (Nanjing Bioengineering Institute, Nanjing, China), according to the manufacturer’s instructions. Intra- and interassay variation were &lt;10% and &lt;15%, respectively.</p>
</sec>
<sec id="sec7-0300060513487650"><title>Statistical analyses</title>
<p>Data were provided as mean ± SD, and non-normally distributed data were log-transformed. Differences between two groups were analysed with Student’s <italic>t</italic>-test or χ<sup>2</sup> test, as appropriate. Linear correlation analysis was performed to identify the correlations among the related indicators. Statistical analyses were performed using SPSS® software, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows®. A <italic>P</italic>-value &lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec8-0300060513487650" sec-type="results"><title>Results</title>
<p>The study recruited 45 control subjects (23 males/22 females; mean age 53.8 ± 6.4 years, range 44–72 years) and 138 patients with AMI. Treatment randomization of the patients meant that 47 participants underwent reperfusion via PCI (23 males/24 females; mean age 53.4 ± 6.3 years, range 45–72 years), 45 underwent reperfusion via thrombolytic therapy (23 males/22 females; mean age 53.7 ± 6.2 years old, range 45–73 years) and 46 received conservative drug therapy (23 males/23 females; mean age 54.1 ± 6.3 years, range 44–71 years). There were no significant between-group differences in sex distribution or patient age.</p>
<p>Data regarding eNOS, NO and ET-1 levels in the four study groups are given in <xref ref-type="table" rid="table1-0300060513487650">Table 1</xref>. Levels of eNOS and NO were significantly lower, and ET-1 levels were significantly higher, in patients who underwent PCI or thrombolytic therapy compared with those who received conservative drug therapy or controls (<italic>P</italic> &lt; 0.01 for each comparison; <xref ref-type="table" rid="table1-0300060513487650">Table 1</xref>). In addition, eNOS and NO levels were significantly lower, whereas ET-1 levels were significantly higher, in the conservative drug therapy group compared with the control group (<italic>P</italic> &lt; 0.01 for each comparison; <xref ref-type="table" rid="table1-0300060513487650">Table 1</xref>). There were no significant differences in eNOS, NO or ET-1 levels between the PCI and thrombolytic therapy groups.
<table-wrap id="table1-0300060513487650" position="float"><label>Table 1.</label><caption><p>Endothelial nitric oxide (NO) synthase (eNOS) activity, and levels of NO (expressed as NO<sup>3−</sup>) and endothelin-1 (ET-1), in patients with acute myocardial infarction (randomized to receive treatment via percutaneous coronary intervention [PCI], thrombolytic therapy or conservative drug therapy) and healthy control subjects.</p></caption>
<graphic alternate-form-of="table1-0300060513487650" xlink:href="10.1177_0300060513487650-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>PCI group <italic>n</italic> = 47</th>
<th>Thrombolytic therapy group <italic>n</italic> = 45</th>
<th>Conservative drug therapy group <italic>n</italic> = 46</th>
<th>Control group <italic>n</italic> = 45</th>
</tr></thead>
<tbody align="left">
<tr>
<td>eNOS, U/ml</td>
<td>4.57 ± 0.16<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>4.99 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>6.35 ± 0.22 <sup>b</sup></td>
<td>7.86 ± 0.19</td>
</tr>
<tr>
<td>NO<sub>3</sub><sup>−</sup>, µmol/l</td>
<td>23.52 ± 15.48<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>24.08 ± 14.97<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>39.47 ± 12.18 <sup>b</sup></td>
<td>60.43 ± 13.58</td>
</tr>
<tr>
<td>ET-1, pg/ml</td>
<td>22.45 ± 5.47<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>20.38 ± 5.16<sup><xref ref-type="table-fn" rid="table-fn2-0300060513487650">a</xref>b</sup></td>
<td>13.27 ± 4.12 <sup>b</sup></td>
<td>6.57 ± 2.19</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513487650"><p>Data presented as mean ± SD.</p></fn>
<fn id="table-fn2-0300060513487650"><label>ab</label><p><italic>P</italic> &lt; 0.01 vs conservative drug therapy group, <italic>P</italic> &lt; 0.01vs control group; Student’s <italic>t</italic>-test.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Linear correlation analysis revealed a significant positive correlation between eNOS and NO, as well as significant negative correlations between eNOS/ET-1 and NO/ET-1 in all four groups (<italic>P</italic> &lt; 0.05 for each correlation; <xref ref-type="table" rid="table2-0300060513487650">Table 2</xref>).
<table-wrap id="table2-0300060513487650" position="float"><label>Table 2.</label><caption><p>Correlation analysis of endothelial nitric oxide (NO) synthase (eNOS) activity, and levels of NO and endothelin-1 (ET-1). in patients with acute myocardial infarction (randomized to receive treatment via percutaneous coronary intervention [PCI], thrombolytic therapy or conservative drug therapy), and healthy control subjects.</p></caption>
<graphic alternate-form-of="table2-0300060513487650" xlink:href="10.1177_0300060513487650-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>PCI group <italic>n</italic> = 47</th>
<th>Thrombolytic therapy group <italic>n</italic> = 45</th>
<th>Conservative drug therapy group <italic>n</italic> = 46</th>
<th>Control group <italic>n</italic> = 45</th>
</tr></thead>
<tbody align="left">
<tr>
<td>eNOS/NO</td>
<td>0.47</td>
<td>0.41</td>
<td>0.48</td>
<td>0.40</td>
</tr>
<tr>
<td>eNOS/ET-1</td>
<td>−0.46</td>
<td>−0.49</td>
<td>−0.45</td>
<td>−0.43</td>
</tr>
<tr>
<td>NO/ET-1</td>
<td>−0.49</td>
<td>−0.42</td>
<td>−0.52</td>
<td>−0.48</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0300060513487650"><p>Data presented as correlation coefficient.</p></fn>
<fn id="table-fn4-0300060513487650"><p><italic>P</italic> &lt; 0.05 for each correlation.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0300060513487650" sec-type="discussion"><title>Discussion</title>
<p>Both AMI and reperfusion therapy are known to cause vascular endothelial function impairment,<sup><xref ref-type="bibr" rid="bibr5-0300060513487650">5</xref></sup> resulting in decreased NO levels and increased ET-1 levels. In addition, early reperfusion therapy effectively improved coronary blood supply for patients with partial AMI, but did not improve NO and ET-1 levels in all patients.<sup><xref ref-type="bibr" rid="bibr13-0300060513487650">13</xref></sup></p>
<p>Right brachial artery flow-mediated vasodilatation and nitroglycerin-mediated vasodilatation have been shown to predict vascular endothelial function accurately,<sup><xref ref-type="bibr" rid="bibr14-0300060513487650">14</xref></sup> and have been used for clinical evaluation of endothelial function.<sup><xref ref-type="bibr" rid="bibr15-0300060513487650">15</xref></sup> Nitroglycerin is an endothelium-independent vasodilator that directly generates NO,<sup><xref ref-type="bibr" rid="bibr16-0300060513487650">16</xref></sup> therefore it is difficult to differentiate between the NO generated by nitroglycerin and that generated by the body. For this reason, the present study used NO and ET-1 for the indirect assessment of vascular endothelial function.</p>
<p>Patients with AMI had significantly lower eNOS and NO levels, and significantly higher ET-1 levels, than control subjects in the present study, regardless of treatment group. Correlation analysis found that eNOS and NO were inversely related to ET-1. A reduction in eNOS may result in lower NO secretion, and a reduction in NO could upregulate ET-1.</p>
<p>Levels of eNOS, NO and ET-1 were similar in the two reperfusion therapy groups (PCI and thrombolytic therapy) in the present study. This suggests that the intervention was not the main cause of endothelial impairment, and that ischaemia–reperfusion impairment remains an important factor.</p>
<p>The present study is limited by the fact that endothelial function was assessed only once, at 24 h after reperfusion therapy. Endothelial impairment caused by reperfusion therapy has been shown to disappear gradually over time, resulting in improved vascular endothelial function.<sup><xref ref-type="bibr" rid="bibr17-0300060513487650">17</xref></sup></p>
<p>In conclusion, the present study found that patients with AMI who underwent reperfusion therapy displayed low eNOS activity. This may result in impairment of endothelial function via downregulation of NO and upregulation of ET-1.</p>
</sec>
</body>
<back>
<sec id="sec10-0300060513487650"><title>Declaration of conflicting interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec11-0300060513487650"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0300060513487650"><label>1</label><citation citation-type="other"><comment>Winckers K, Ten Cate H, Hackeng TM. The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. <italic>Blood Rev</italic> 2013 Apr 27; doi: pii: S0268-960X(13)00016-7. 10.1016/j.blre.2013.03.001</comment>.</citation></ref>
<ref id="bibr2-0300060513487650"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herlitz</surname><given-names>J</given-names></name><name><surname>Dellborg</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Epidemiology of acute myocardial infarction with the emphasis on patients who did not reach the coronary care unit and non-AMI admissions</article-title>. <source>Int J Cardiol</source> <year>2008</year>; <volume>128</volume>: <fpage>342</fpage>–<lpage>349</lpage>.</citation></ref>
<ref id="bibr3-0300060513487650"><label>3</label><citation citation-type="other"><comment>Suematsu Y, Murasato Y, et al. Safety and feasibility of high-dose administration of nicorandil before reperfusion therapy in acute myocardial infarction. <italic>Cardiovasc Interv Ther</italic> 2013 Apr 27. Epub ahead of print</comment>.</citation></ref>
<ref id="bibr4-0300060513487650"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grybauskas</surname><given-names>P</given-names></name></person-group>. <article-title>[Role of tissue factor in atherothrombosis]</article-title>. <source>Medicina (Kaunas)</source> <year>2003</year>; <volume>39</volume>: <fpage>1165</fpage>–<lpage>1170</lpage>.</citation></ref>
<ref id="bibr5-0300060513487650"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrabés</surname><given-names>JA</given-names></name></person-group>. <article-title>Endothelial function in infarct-related arteries: does the type of reperfusion therapy matter?</article-title> <source>Rev Esp Cardiol</source> <year>2008</year>; <volume>61</volume>: <fpage>797</fpage>–<lpage>799</lpage>.</citation></ref>
<ref id="bibr6-0300060513487650"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>GP</given-names></name><name><surname>Maiolino</surname><given-names>G</given-names></name><name><surname>Zanchetta</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The T(-786)C endothelial nitric oxide synthase genotype pedicts cardiovascular mortality in high-risk patients</article-title>. <source>J Am Coll Cardiol</source> <year>2006</year>; <volume>48</volume>: <fpage>1166</fpage>–<lpage>1174</lpage>.</citation></ref>
<ref id="bibr7-0300060513487650"><label>7</label><citation citation-type="other"><comment>Wang H and Eitzman DT. Acute myocardial infarction leads to acceleration of atherosclerosis. <italic>Atherosclerosis</italic> 2013 Apr 12; doi: 10.1016/j.atherosclerosis.2013.04.004</comment>.</citation></ref>
<ref id="bibr8-0300060513487650"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J-L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Relationship between endothelial nitric oxide synthase, insulin resistance and macrovascular disease in patients with acute myocardial infarction</article-title>. <source>J Int Med Res</source> <year>2012</year>; <volume>40</volume>: <fpage>687</fpage>–<lpage>693</lpage>.</citation></ref>
<ref id="bibr9-0300060513487650"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antoniades</surname><given-names>C</given-names></name><name><surname>Shirodaria</surname><given-names>C</given-names></name><name><surname>Crabtree</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>: <fpage>2851</fpage>–<lpage>2859</lpage>.</citation></ref>
<ref id="bibr10-0300060513487650"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casas</surname><given-names>JP</given-names></name><name><surname>Cavalleri</surname><given-names>GL</given-names></name><name><surname>Bautista</surname><given-names>LE</given-names></name><etal/></person-group>. <article-title>Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review</article-title>. <source>Am J Epidemiol</source> <year>2006</year>; <volume>164</volume>: <fpage>921</fpage>–<lpage>935</lpage>.</citation></ref>
<ref id="bibr11-0300060513487650"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><etal/></person-group>. <article-title>Universal definition of myocardial infarction</article-title>. <source>J Am Coll Cardiol</source> <year>2007</year>; <volume>50</volume>: <fpage>2173</fpage>–<lpage>2195</lpage>.</citation></ref>
<ref id="bibr12-0300060513487650"><label>12</label><citation citation-type="other"><comment>WMA. Declaration of Helsinki, <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/20activities/10ethics/10helsinki/"><italic>http://www.wma.net/en/20activities/10ethics/10helsinki/</italic></ext-link>2008 (Accessed 08 May 2013)</comment>.</citation></ref>
<ref id="bibr13-0300060513487650"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D’Errigo</surname><given-names>P</given-names></name><name><surname>Seccareccia</surname><given-names>F</given-names></name><name><surname>Barone</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Effectiveness of invasive reperfusion therapy and standard medical treatment in AMI</article-title>. <source>Acta Cardiol</source> <year>2010</year>; <volume>65</volume>: <fpage>645</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr14-0300060513487650"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akamatsu</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease</article-title>. <source>J Atheroscler Thromb</source> <year>2010</year>; <volume>17</volume>: <fpage>1266</fpage>–<lpage>1274</lpage>.</citation></ref>
<ref id="bibr15-0300060513487650"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hardie</surname><given-names>KL</given-names></name><name><surname>Kinlay</surname><given-names>S</given-names></name><name><surname>Hardy</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function</article-title>. <source>Aust N Z J Med</source> <year>1997</year>; <volume>27</volume>: <fpage>649</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr16-0300060513487650"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Sudhahar</surname><given-names>V</given-names></name><name><surname>Ansenberger-Fricano</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway</article-title>. <source>Free Radic Biol Med</source> <year>2012</year>; <volume>52</volume>: <fpage>427</fpage>–<lpage>435</lpage>.</citation></ref>
<ref id="bibr17-0300060513487650"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlucci</surname><given-names>F</given-names></name><name><surname>Tabucchi</surname><given-names>A</given-names></name><name><surname>Biagioli</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Cardiac surgery: myocardial energy balance, antioxidant status and endothelial function after ischemia-reperfusion</article-title>. <source>Biomed Pharmacother</source> <year>2002</year>; <volume>56</volume>: <fpage>483</fpage>–<lpage>491</lpage>.</citation></ref>
</ref-list>
</back>
</article>